Increasing Specificity and Sensitivity in Routine Peptide Analyses Using Mass Detection with the ACQUITY QDa Detector

Importance of the Topic

The reliable identification and quantification of peptide fragments are fundamental in biotherapeutic development and quality control. Optical detection alone can miss coeluting species or subtle modifications that affect product safety and efficacy. Integrating mass detection enhances assay specificity, expands dynamic range, and strengthens confidence in peptide mapping workflows.

Objectives and Study Overview

This study demonstrates how the ACQUITY QDa Detector, coupled with Empower 3 Chromatography Data Software, can be seamlessly added to existing UPLC–UV peptide assays. The goal is to show improved specificity and sensitivity for routine peptide monitoring, particularly for critical quality attribute (CQA) assessment in monoclonal antibody digest mapping.

Methodology and Instrumentation

Sample Preparation and LC Conditions:

• Digest of reduced and alkylated trastuzumab prepared with sequence-grade trypsin at 0.5 mg/mL.
• ACQUITY UPLC Peptide CSH C18 Column (130 Å, 1.7 µm, 2.1 × 100 mm) at 65 °C, flow 0.2 mL/min.
• Mobile phases: A) H₂O/0.1% formic acid; B) acetonitrile/0.1% formic acid.

Instrumentation and Detection:

• ACQUITY UPLC H-Class System.
• ACQUITY UPLC Tunable UV Detector at 215 nm.
• ACQUITY QDa Detector: mass range 350–1250 Da, capillary voltage 1.5 kV, probe temp. 500 °C, cone voltage 10 V.
• Empower 3 SR2 Software for simultaneous optical and mass data acquisition and processing.

Main Results and Discussion

Optical traces revealed coelution of the complementary determining region (CDR) peptide (L3) with neighboring species and its deamidated form (L3D), obscuring accurate CQA assessment. Extracted ion chromatograms (XICs) generated from QDa data confirmed multiple coeluting peptides in the same retention window. By programming timed Single-Ion Recording (SIR) events for specific +2 and +3 charge states of L3 and L3D, each species was recorded with high signal-to-noise, free from interfering peaks. An inter-channel calculation within Empower 3 facilitated relative quantification, determining 8.28% deamidation for the L3 peptide in a single run.

Benefits and Practical Applications

Incorporating the QDa Detector into routine peptide mapping workflows offers:

• Orthogonal confirmation of peak identity and homogeneity without altering existing chromatographic methods.
• Enhanced specificity through timed SIRs, reducing false positives from coeluting species.
• Rapid inter-channel quantification of modification levels, streamlining CQA monitoring in development and QC labs.
• Cost-effective upgrade to GMP-compliant workflows using standard Empower Software features.

Future Trends and Opportunities

Compact mass detectors are poised to become standard companions to UV systems in regulated environments. Anticipated developments include:

• Automated method development integrating UV and MS data for optimal separation and detection.
• Machine-learning algorithms in CDS platforms to predict and flag coeluting or modified species in real time.
• Broader adoption for glycopeptide profiling, impurity analysis, and biosimilar comparability studies.
• Integration with high-resolution MS for detailed characterization of low-abundance peptides and post-translational modifications.

Conclusion

The ACQUITY QDa Detector, when combined with Empower 3 Software, delivers a straightforward and cost-effective solution to enhance specificity and sensitivity in routine peptide analyses. This approach strengthens CQA monitoring by providing orthogonal mass confirmation without compromising throughput or requiring extensive method reoptimization.

Reference

1. Rathore A, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol. 2009;27(1):26–34.
2. Goetze A, Schenauer M, Flynn G. Assessing monoclonal antibody product quality attribute criticality through clinical studies. mAbs. 2010;2(5):500–7.
3. Birdsall R, Cosgrave E, McCarthy S. Adding Mass Detection to Routine Peptide-Level Biotherapeutic Analyses with the ACQUITY QDa Detector. Waters Application Note. 2015;720005266EN.
4. Vlasak J, et al. Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal Biochem. 2009;392(2):14–54.
5. Harris R, Kabakoff B, Macchi F, et al. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl. 2001;752(2):233–45.